2023. gads medicina: medikamenti, lai apstadinatu Alcheimeru, gan apturetu aptaukosanos
b'Aizvad\\u012btais gads medic\\u012bn\\u0101 mums paliks atmi\\u0146\\u0101 ar daudziem \\u201cpirmajiem\\u201d: pirmie medikamenti, kas apst\\u0101din\\u0101tu agr\\u012bnu Alcheimera slim\\u012bbu, za\\u013c\\u0101 gaisma pirmajai CRISPR g\\u0113nu redi\\u0123\\u0113\\u0161anas terapijai, pirmie medikamenti, kas pal\\u012bdz\\u0113tu smagaj\\u0101 c\\u012b\\u0146\\u0101 ar aptauko\\u0161anos un jaunas vakc\\u012bnas pret da\\u017e\\u0101d\\u0101m slim\\u012bb\\u0101m. Ko 2023. gads sniedza mums medic\\u012bn\\u0101? Apzinoties, ka visus aspektus vien\\u0101 sarun\\u0101 izrun\\u0101t nevaram, \\u0161aj\\u0101 raid\\u012bjum\\u0101 piev\\u0113rs\\u012bsimies v\\u0113\\u017ea izp\\u0113tei un terapijai, k\\u0101 ar\\u012b jaunumiem Alcheimera \\u0101rst\\u0113\\u0161an\\u0101. Saruna ar R\\u012bgas Stradi\\u0146a universit\\u0101tes asoci\\u0113to profesori, neirolo\\u0123i Zandu Priedi un Latvijas Universit\\u0101tes profesoru, Latvijas Universit\\u0101tes Kl\\u012bnisk\\u0101s un profilaktisk\\u0101s medic\\u012bnas instit\\u016bta direktoru, gastroenterologu M\\u0101rci Leju.\\n\\nAlcheimers ir neirode\\u0123enerat\\u012bva saslim\\u0161ana, kuru ir neiesp\\u0113jami padar\\u012bt par nebiju\\u0161u br\\u012bd\\u012b, kad slim\\u012bbas process jau ir s\\u0101cies. 2023. gads nebija pirmais, kad pasaul\\u0113 visp\\u0101r run\\u0101ja par medikamentiem pret Alcheimeru, tom\\u0113r z\\u0101\\u013cu izstr\\u0101d\\u0113 pag\\u0101ju\\u0161ais gads ir bijis noz\\u012bm\\u012bgs.\\n\\n"P\\u0113t\\u012bjumi ir \\u013coti ilgi, jo smadze\\u0146u neirode\\u0123ener\\u0101cijas process tas nav viena, divu m\\u0113ne\\u0161u jaut\\u0101jums, tas ir process vair\\u0101ku gadu garum\\u0101. P\\u0113d\\u0113jos 20 gadus p\\u0113tniec\\u012bb\\u0101 nebija n\\u0101cis neviens re\\u0101ls medikaments, kas var\\u0113tu ietekm\\u0113t smadze\\u0146u neirode\\u0123ener\\u0101cijas meh\\u0101nismu. \\u0160is ir sasniegums specifisk\\u0101 im\\u016bnterapijas pieej\\u0101 tie\\u0161i Alcheimera slim\\u012bbas vien\\u0101 no pato\\u0123en\\u0113zes meh\\u0101nismiem. Im\\u016bnterapija, kas v\\u0113rsta pret konkr\\u0113tu prote\\u012bnu, lai \\u0161\\u012bs pl\\u0101ksn\\u012btes, kas smadzen\\u0113s akumul\\u0113jas un ierosina \\u0161o neirode\\u0123ener\\u0101cijas procesu, tiktu iz\\u0161\\u0137\\u012bdin\\u0101tas un evaku\\u0113tas no smadzen\\u0113m. Lai l\\u012bdz \\u0161im tiktu, p\\u0113t\\u012bjumi norisin\\u0101j\\u0101s jau 30 gadus," skaidro Zanda Priede.\\n\\nTas ir gana liels periods cilv\\u0113cei. Zanda Priede atz\\u012bst, ka tas, ka ASV jau ir apstiprin\\u0101ju\\u0161as izstr\\u0101d\\u0101to z\\u0101\\u013cu izmanto\\u0161anu, ir liela uzvara.\\n\\n"Ar\\u012b lai m\\u0113s tiktu l\\u012bdz \\u0161\\u012b medikamenta ievie\\u0161anas praktisk\\u0101 lieto\\u0161an\\u0101 ir v\\u0113l gar\\u0161 ce\\u013c\\u0161 ejams, ne tikai Eirop\\u0101 un Latvij\\u0101, nor\\u0101da Priede.\\n\\nVi\\u0146a atz\\u012bst, ka jau p\\u0113t\\u012bjumu gait\\u0101 veikta r\\u016bp\\u012bga cilv\\u0113ku atlase un \\u013coti daudzi cilv\\u0113ki nevar\\u0113ja piedal\\u012bties, tas noz\\u012bm\\u0113, ka ar\\u012b ikdienas praks\\u0113 \\u0101rstiem b\\u016bs gr\\u016bts uzdevums noteikt, kuram pacientam, kur\\u0101 br\\u012bd\\u012b un kad uzs\\u0101kt medikamenta lieto\\u0161anu. Tas b\\u016bs n\\u0101kamais svar\\u012bgais jaut\\u0101jums.'